{"id":"placebo-via-diskus","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL4848060","moleculeType":"Unknown","molecularWeight":"1965.37"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo is a pharmacologically inactive substance administered in the same formulation and route as an active drug. It relies on the placebo effect—the therapeutic benefit derived from patient expectation and the clinical context—rather than any direct molecular mechanism. In this case, it is delivered via the DISKUS dry powder inhaler device.","oneSentence":"Placebo produces no pharmacological effect and serves as an inert control in clinical trials and research studies.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:01:31.361Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in clinical trials (not a therapeutic indication)"}]},"trialDetails":[{"nctId":"NCT02245672","phase":"PHASE3","title":"MGR001 / Advair Diskus Local Equivalence Study in Asthma","status":"COMPLETED","sponsor":"Mylan Pharma UK Ltd.","startDate":"2014-10","conditions":"Asthma","enrollment":1128},{"nctId":"NCT00674817","phase":"PHASE2","title":"An Investigation Of The Interaction Of GSK961081 With Inhaled Beta-Agonist And Anti-Muscarinic Drugs.","status":"COMPLETED","sponsor":"Theravance Biopharma","startDate":"2008-04-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":45},{"nctId":"NCT00550225","phase":"PHASE1","title":"Succinate Salt Version of GSK961081 for Healthy Volunteers","status":"COMPLETED","sponsor":"Theravance Biopharma","startDate":"2007-11-29","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":18},{"nctId":"NCT02522299","phase":"PHASE2","title":"A Study to Evaluate the Safety, Efficacy and Changes in Induced Sputum and Blood Biomarkers Following Daily Repeat Doses of Inhaled GSK2269557 in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Acute Exacerbation","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-11-04","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":44},{"nctId":"NCT02294734","phase":"PHASE2","title":"An Efficacy Study of GSK2269557 Added to Standard Care in Subjects With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-03-31","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":126},{"nctId":"NCT02991859","phase":"PHASE2","title":"Phase 2a, AMP Challenge, Dose Escalation Study to Assess the Dose Response for Topical Efficacy and Systemic Activity in Asthmatic Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-02-09","conditions":"Asthma","enrollment":56},{"nctId":"NCT03227445","phase":"PHASE4","title":"Comparative Study of ELLIPTA Dry Powder Inhaler (DPI) Versus DISKUS DPI Used With HandiHaler DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-09-20","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":240},{"nctId":"NCT03034915","phase":"PHASE4","title":"A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-06-16","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":2696},{"nctId":"NCT03535870","phase":"NA","title":"Clinical Endpoint Bioequivalence Study of Fluticasone Propionate & Salmeterol Xinafoate (100μg/50μg)","status":"COMPLETED","sponsor":"West-Ward Pharmaceutical","startDate":"2018-04-26","conditions":"Asthma","enrollment":1556},{"nctId":"NCT02730351","phase":"PHASE4","title":"Crossover Study Comparing Fluticasone Furoate (FF)/Vilanterol (VI) Once Daily Versus Fluticasone Propionate (FP) Twice Daily in Subjects With Asthma and Exercise-Induced Bronchoconstriction (EIB)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-05-25","conditions":"Asthma","enrollment":75},{"nctId":"NCT01494610","phase":"PHASE1, PHASE2","title":"Pharmacokinetic and Pharmacodynamic (PK and PD) Study of Fluticasone Propionate and Salmeterol Combination Product Delivered in a Capsule-based Inhaler and in a Multi-dose Dry Powder Inhaler in Moderate Asthma Patients and Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-10-25","conditions":"Asthma","enrollment":60},{"nctId":"NCT02301975","phase":"PHASE3","title":"An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-03-01","conditions":"Asthma","enrollment":1526},{"nctId":"NCT02567708","phase":"PHASE2","title":"A Study to Investigate the Efficacy, Safety, and Tolerability of Repeat Doses of Inhaled GSK2269557 in Adults With Persistent, Uncontrolled Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-10-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":50},{"nctId":"NCT01576718","phase":"PHASE2","title":"A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2012-04","conditions":"Asthma","enrollment":889},{"nctId":"NCT01706328","phase":"PHASE3","title":"A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-10-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":828},{"nctId":"NCT00372112","phase":"PHASE2","title":"A Study To Assess The Safety And Tolerability Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-11-03","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":68},{"nctId":"NCT02649478","phase":"NA","title":"Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate","status":"COMPLETED","sponsor":"Roxane Laboratories","startDate":"2014-08","conditions":"Asthma","enrollment":1430},{"nctId":"NCT01817764","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-03-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":707},{"nctId":"NCT01879410","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-06-13","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":700},{"nctId":"NCT01181895","phase":"PHASE3","title":"Study B2C112060: A Study of the Efficacy and Safety of Vilanterol Inhalation Powder in Adults and Adolescents With Persistent Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-09-01","conditions":"Asthma","enrollment":348},{"nctId":"NCT01147744","phase":"PHASE2","title":"Dose Ranging Study Evaluating the Efficacy and Safety of GSK2190915 Administered Once Daily","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-06-28","conditions":"Asthma","enrollment":700},{"nctId":"NCT00279019","phase":"PHASE1","title":"Safety Study Using GSK233705 And Tiotropium In Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-12-12","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":31},{"nctId":"NCT00555022","phase":"PHASE1","title":"Effect of GSK1160724 In Healthy Volunteers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-12-12","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":21},{"nctId":"NCT01822899","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-04-04","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":717},{"nctId":"NCT00463697","phase":"PHASE1","title":"A Study To Investigate The Effect Of Inhaling A Single Dose Of GW642444M In Asthmatic Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-04-02","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":20},{"nctId":"NCT00444509","phase":"PHASE1","title":"Single Dose GW685698X Magnesium Stearate Study In Asthmatic Patients.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-02-17","conditions":"Asthma","enrollment":20},{"nctId":"NCT00522678","phase":"PHASE1","title":"Repeat Dose GW685698X With Magnesium Stearate, Excipient Bridging Study, In Healthy Volunteers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-02-15","conditions":"Asthma","enrollment":36},{"nctId":"NCT01449799","phase":"PHASE1","title":"An Investigation of the Pharmacokinetics of GSK961081 and Fluticasone Propionate in Healthy Volunteers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-07-13","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":24},{"nctId":"NCT02260492","phase":"PHASE1","title":"Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in Asthma","status":"COMPLETED","sponsor":"Oriel Therapeutics","startDate":"2014-09","conditions":"Asthma","enrollment":879},{"nctId":"NCT01479621","phase":"PHASE2","title":"A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2012-01","conditions":"Asthma","enrollment":909},{"nctId":"NCT02416180","phase":"PHASE4","title":"Study to Evaluate Handling Errors in Usage of SERETIDE® Metered Dose Inhaler (MDI) (EVOHALER®) by Adult Subjects Currently Using the SERETIDE DISKUS® Inhaler","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-06-18","conditions":"Asthma","enrollment":111},{"nctId":"NCT00268216","phase":"PHASE3","title":"Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2000-09","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":6228},{"nctId":"NCT01436110","phase":"PHASE3","title":"Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate and Fluticasone Propionate in People With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-09","conditions":"Asthma","enrollment":351},{"nctId":"NCT00741767","phase":"NA","title":"The Impact of Salmeterol-Fluticasone on Sleep in Patients With COPD","status":"WITHDRAWN","sponsor":"Northwestern University","startDate":"2008-08","conditions":"Chronic Obstructive Pulmonary Disease, Sleep Disorders","enrollment":""},{"nctId":"NCT02218762","phase":"PHASE1","title":"A Study in Patients With Moderate Asthma to Compare Pharmacokinetics and Pharmacodynamic Effects of Fluticasone Propionate and Salmeterol Delivered Via the ROTAHALER® Inhaler Relative to the DISKUS® Inhaler","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2014-10","conditions":"Asthma","enrollment":""},{"nctId":"NCT02242227","phase":"PHASE2","title":"Efficacy, Pharmacokinetics and Safety Comparison of Salmeterol Inhalation Powder Administered Via the HandiHaler® 2 and Serevent® Diskus® in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2005-09","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":111},{"nctId":"NCT02238106","phase":"PHASE2","title":"Salmeterol Inhalation Powder Administered as the Xinafoate Salt From Hard Polyethylene Capsules Via the HandiHaler® 2, and Serevent® Diskus® in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2005-09","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":136},{"nctId":"NCT00531050","phase":"PHASE2","title":"Safety of Exercise and High-dose Salbutamol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Receiving Therapeutic Doses of Indacaterol (QAB 149) and Salmeterol","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-08","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":27},{"nctId":"NCT01079130","phase":"PHASE3","title":"Efficacy and Safety of Different Doses of Indacaterol","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-02","conditions":"Asthma","enrollment":511},{"nctId":"NCT01089127","phase":"PHASE3","title":"Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-03","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":552},{"nctId":"NCT00821093","phase":"PHASE3","title":"Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-01","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1123},{"nctId":"NCT00403754","phase":"PHASE2","title":"Dose Ranging Study for Indacaterol in Japanese Asthma Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-11","conditions":"Asthma","enrollment":41},{"nctId":"NCT00655616","phase":"NA","title":"Add-on Salmeterol Versus Montelukast in Arg/Arg-16 Asthmatics","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2007-08","conditions":"Asthma","enrollment":64}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":34,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Placebo via DISKUS","genericName":"Placebo via DISKUS","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Placebo produces no pharmacological effect and serves as an inert control in clinical trials and research studies. Used for Control arm in clinical trials (not a therapeutic indication).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}